Melanoma Coverage from Every Angle

Recent News

TAT 2020: Trametinib and Low-Dose Dabrafenib in Advanced BRAF V600 Wild-Type Melanoma
Encorafenib/Binimetinib in BRAF V600–Mutated Melanoma: COLUMBUS Trial Survival Update
Bempegaldesleukin and Adoptive Cell Transfer Therapy: Preclinical Melanoma Model
Can Circular RNA Block Melanoma Metastasis?
How Biologists Are Using Zebrafish to Study Treatment of Melanoma
ASCO-SITC 2020: Sociodemographics and Receipt of Immunotherapy in Advanced Melanoma
Can Influenza Vaccines Trigger Immune Response in Patients With Melanoma?
Insights Into Therapeutic Resistance in Leptomeningeal Melanoma Metastases
Can B Cells Determine Immunotherapy Responses in Advanced Melanoma?
Heterogeneity Among Circulating Tumor Cells in Advanced Melanoma
Preclinical Study Explores BH3 Mimetic Combinations in Melanoma
‘Priming’ Patients With Advanced Melanoma for Retreatment With Checkpoint Inhibitors
Two-Year Survival Results With Neoadjuvant T-VEC in Resectable Melanoma
SMR 2019: T-VEC Plus Ipilimumab in Advanced Melanoma
SMR 2019: Tumor-Infiltrating Lymphocyte Therapy for Refractory Metastatic Melanoma
SMR 2019: Nivolumab Plus Ipilimumab and Nivolumab Alone in Advanced Melanoma
SMR 2019: Vaccine Under Study to Prevent Recurrence in High-Risk Advanced Melanoma
ABC Trial: Nivolumab Plus Ipilimumab for Melanoma Brain Metastases
Triplet Regimen for BRAF-Mutated Metastatic Melanoma
SITC 2019: Adding IL-2 Agonist to Nivolumab in Metastatic Melanoma
SITC 2019: Adenovirus Plus Pembrolizumab in Resistant Melanoma
Nivolumab and Ipilimumab in Melanoma: OpACIN Trial Follow-up
Can Second Opinions From Pathologists Improve Melanoma Diagnoses?
The Wistar Institute Awarded $12.5M Grant for Melanoma Targeted Therapies
ESMO 2019: Neoadjuvant Talimogene Laherparepvec in Advanced Resectable Melanoma
New $1M Grants for Research on Melanoma Metastasis
ESMO 2019: Cobimetinib Plus Atezolizumab Versus Pembrolizumab in BRAF V600 Wild-Type Melanoma
ESMO 2019: Update From CheckMate 238 of Nivolumab Versus Ipilimumab in Advanced Melanoma
ESMO 2019: 5-Year Survival Data on Nivolumab Plus Ipilimumab in Advanced Melanoma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.